OR WAIT 15 SECS
Lash Group started more than 30 years ago with a passion for patients. Our pioneering vision to connect patients more quickly and efficiently to better care has transformed an industry, and we remain dedicated to helping people access, afford and remain on the treatments they need.
As the Vice President of Product Innovation and Analytics, Myra Reinhardt brings extensive experience and expertise in strategic planning, product development and deploying large-scale technology solutions. Focused on product and analytics, she is responsible for the delivery and implementation of solutions that support the growth of the Lash Group business.
As specialty therapies evolve and more treatment options for chronic and complex diseases become available, patients are seeking treatment options that are both effective and affordable.
As specialty therapies evolve and more treatment options for chronic and complex diseases become available, patients are seeking treatment options that are both effective and affordable. Helping patients access their prescribed therapy faster and more easily is key to improving outcomes.
Electronic benefit verification (eBV) has emerged as an efficient method for allowing providers to verify a patient’s coverage while in the office and reducing delays in time to therapy. But as eBV technology and methodologies evolve, manufacturers may find themselves overwhelmed with options-and questions-as they design patient access solutions. For example, can the process be too streamlined? Where does eBV add value to the therapy on-boarding experience? When is a comprehensive BV the best approach?
eBV options on the market today
To make an accurate assessment of your options as a manufacturer, you'll need an understanding of where different solutions source the benefits information they return. Here's an overview of the most common methods:
Choose a patient-centric solution from a consultative partner
Which model makes the most sense for your product? Taking into account the coverage mix and volume of your patient population will help you choose the most appropriate eBV methodology. The payer surveillance approach is most viable for patient populations made up of mostly Medicare eligible beneficiaries. If a significant portion of the population has commercial insurance, a rules-based model could work better, and a predictive model is the best option. Patient volumes will influence the effectiveness of all solution types. Smaller patient populations that are typically seen in orphan products require special consideration when evaluating options.
The value of AI
Determining whether to invest in a system with advanced technology capability is critical. It's rather like deciding if the latest smartphone will meet your personal needs better than a flip phone.
If your needs are basic and you only make a few calls a month, a flip phone will probably fit the bill. If you have frequent touchpoints with contacts via many channels (text, social media, phone, apps, etc.), you'll want to go with a smartphone. Likewise, a program with predominantly uniform insurance coverage has simpler benefit verification needs; therefore, a payer surveillance system could offer the right value.
For a program that requires a more sophisticated eBV solution, the advanced underlying technology and related services to support, groom, and develop the technology will ultimately deliver incrementally more value. It streamlines workflows, lowers administrative costs, improves patient and provider experience, and improves outcomes.
A predictive eBV system has the greatest benefit when it blends AI and machine-learning technologies with the expertise of humans. This truly comprehensive eBV solution continually improves the precision of the results and gives patients better and faster access to therapy.
As these technologies keep evolving and advancing, there is an opportunity to combine all three methodologies to offer an even more robust eBV experience.
Related Content:Lash Group